MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, IRWD had $47,555K increase in cash & cash equivalents over the period. $47,581K in free cash flow.

Cash Flow Overview

Change in Cash
$47,555K
Free Cash flow
$47,581K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net income (loss)
40,080 -13,787
Depreciation and amortization
475 946
Loss on disposal of property and equipment
-7 -85
Share-based compensation expense
3,612 9,815
Non-cash interest expense
418 832
Non-cash lease expense
426 827
Deferred income taxes
27,772 14,775
Accounts receivable, net
34,193 4,282
Prepaid expenses and other current assets
248 471
Other assets
-63 -284
Accounts payable and accrued expenses
10,693 -4,174
Accrued research and development costs
-1,168 -2,664
Operating lease liabilities
-603 -1,156
Other liabilities
249 3,856
Net cash provided by operating activities
47,583 4,886
Purchases of property and equipment
2 33
Net cash used in investing activities
-2 -33
Proceeds from exercise of stock options and employee stock purchase plan
0 94
Net cash provided by (used in) financing activities
0 94
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-26 -654
Net increase (decrease) in cash and cash equivalents
47,555 4,293
Cash and cash equivalents at beginning of period
88,559 -
Cash and cash equivalents at end of period
140,407 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

IRONWOOD PHARMACEUTICALS INC (IRWD)

IRONWOOD PHARMACEUTICALS INC (IRWD)